PGEN Healthcare

Precigen, Inc.

$5.25+2.14%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 1.9B USD
Enterprise value: 2.3B USD
Full-time employees: 160

Overall health

Strength: growing faster than most peersgrowing faster than peers
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.02 vs a peer median of 0.63) and more debt relative to equity (2.15× vs a peer median of 0.22×)higher risk: bigger price swings (beta 1.02 vs peers 0.63) and more debt vs equity (2.15× vs peers 0.22×)

Ranks #949 of 1,157 healthcare companies (bottom 19%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 72% from December 2022 to July 2026.
Precigen had 72% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Precigen had 72% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Stock-based pay is a large cost. Stock pay was 112% of revenue in 2025.
Precigen paid employees $11M in stock in 2025, 112% of its $10M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Precigen looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Growing fast, still losing money. Revenue grew faster than 95% of peers, at an operating loss.
Revenue grew faster than 95% of peers, but the business runs at an operating loss (margin -46%).

StockQuotient Score

32/ 100

Oct 5 32 → Nov 4 32

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-8.4%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-1.9%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-6.1%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield2.3%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

94/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 171.3%

Why

Stronger than most peers on:

▲ Revenue growth
▲ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

The loss per share widened33% base weight · Z-score -1.20Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth57.1%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 6.10Sector median: 0.0584 · MAD: 0.0840

Revenue growth146.7%

Yahoo Finance fallback · SEC figure unavailable or out of date · fiscal year to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score 10.15Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

17/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROA
▼ Operating margin
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-46.1%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.37Sector median: 0.0706 · MAD: 0.1217

Return on assets-92.6%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -11.22Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-25.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -3.03Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin53.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-361.8%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Debt / equity
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.02

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.16Sector median: 0.6250 · MAD: 0.3380

Current ratio4.58×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.44Sector median: 2.5860 · MAD: 1.3850

Debt / equity2.15×

SEC filings · latest balance sheetReported value33% base weight · Z-score -9.48Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Precigen

Is Precigen getting weaker?: Its latest SEC filing (Aug 4, 2026) showed no major changes. Its overall score is unchanged at 32/100 since Oct 28, 2026.
How is Precigen valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -8.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -8.4% vs peers 1.5% (weaker than 100% of peers).
Is Precigen growing?: Yes, faster than most of its peers. Growth scores 94/100 against 1,393 healthcare peers. Revenue growth 146.7% vs a peer median of 6.1% (stronger than 95% of peers).Revenue growth 146.7% vs peers 6.1% (stronger than 95% of peers).
How profitable is Precigen?: Less profitable than most of its peers. Profitability scores 17/100 against 1,393 healthcare peers. Return on assets -92.6% vs a peer median of 1.7% (weaker than 100% of peers).Return on assets -92.6% vs peers 1.7% (weaker than 100% of peers).
How risky is Precigen?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 4.58× vs a peer median of 2.59× (stronger than 70% of peers).Current ratio 4.58× vs peers 2.59× (stronger than 70% of peers). Debt / equity 2.15× vs a peer median of 0.22× (weaker than 89% of peers).Debt / equity 2.15× vs peers 0.22× (weaker than 89% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 4, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

Worth watching: Precigen is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	31.6M USD	85.7M USD	+171.3%
Net income (12 months)	−204.4M USD	−157.7M USD	−22.9%
Operating margin	-297.2%	-46.1%	+251.1 pts
Free cash flow (12 months)	−117.0M USD	−115.2M USD	−1.5%
Debt	93.5M USD	93.9M USD	+0.4%
Cash	7.5M USD	16.3M USD	+118.3%
Shares outstanding	356.5M	358.0M	+0.4%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	—	—	-1602.5%	-3440.2%	-1141.1%	▲ >999 pts
Net margin	-646.0%	105.2%	-1540.6%	-3216.2%	-2588.2%	▲ 628 pts
Return on assets (ROA)	-25.6%	13.1%	-63.5%	-86.9%	-161.2%	▼ 74 pts
Return on equity (ROE)	-85.9%	22.4%	-80.9%	-327.8%	-1198.6%	▼ 871 pts
Free cash flow margin	-441.7%	-260.0%	-1099.9%	-1955.6%	-927.6%	▲ >999 pts
Current ratio	4.52×	1.50×	2.99×	4.76×	3.09×	▼ 35%
Quick ratio	—	—	—	4.76×	3.08×	▼ 35%
Debt to equity	1.68×	0.68×	0.00×	0.00×	4.46×	—
Interest coverage	—	—	-213.16×	-22504.83×	-28.58×	▲ 100%

PGEN price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 1.02 vs a peer median of 0.63) and more debt relative to equity (2.15× vs a peer median of 0.22×)higher risk: bigger price swings (beta 1.02 vs peers 0.63) and more debt vs equity (2.15× vs peers 0.22×)

Ranks #949 of 1,157 healthcare companies (bottom 19%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 72% from December 2022 to July 2026.

Precigen had 72% more shares at July 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Precigen had 72% more shares at July 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Stock-based pay is a large cost. Stock pay was 112% of revenue in 2025.

Precigen paid employees $11M in stock in 2025, 112% of its $10M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Precigen looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Growing fast, still losing money. Revenue grew faster than 95% of peers, at an operating loss.

Revenue grew faster than 95% of peers, but the business runs at an operating loss (margin -46%).

Questions investors ask about Precigen

Is Precigen getting weaker?

Its latest SEC filing (Aug 4, 2026) showed no major changes. Its overall score is unchanged at 32/100 since Oct 28, 2026.

How is Precigen valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -8.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -8.4% vs peers 1.5% (weaker than 100% of peers).

Is Precigen growing?

Yes, faster than most of its peers. Growth scores 94/100 against 1,393 healthcare peers. Revenue growth 146.7% vs a peer median of 6.1% (stronger than 95% of peers).Revenue growth 146.7% vs peers 6.1% (stronger than 95% of peers).

How profitable is Precigen?

Less profitable than most of its peers. Profitability scores 17/100 against 1,393 healthcare peers. Return on assets -92.6% vs a peer median of 1.7% (weaker than 100% of peers).Return on assets -92.6% vs peers 1.7% (weaker than 100% of peers).

How risky is Precigen?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 4.58× vs a peer median of 2.59× (stronger than 70% of peers).Current ratio 4.58× vs peers 2.59× (stronger than 70% of peers). Debt / equity 2.15× vs a peer median of 0.22× (weaker than 89% of peers).Debt / equity 2.15× vs peers 0.22× (weaker than 89% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

31.6M USD

85.7M USD

+171.3%

Net income (12 months)

−204.4M USD

−157.7M USD

−22.9%

Operating margin

-297.2%

-46.1%

+251.1 pts

Free cash flow (12 months)

−117.0M USD

−115.2M USD

−1.5%

Debt

93.5M USD

93.9M USD

+0.4%

Cash

7.5M USD

16.3M USD

+118.3%

Shares outstanding

356.5M

358.0M

+0.4%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

—

-1602.5%

-3440.2%

-1141.1%

▲ >999 pts

Net margin

-646.0%

105.2%

-1540.6%

-3216.2%

-2588.2%

▲ 628 pts

Return on assets (ROA)

-25.6%

13.1%

-63.5%

-86.9%

-161.2%

▼ 74 pts

Return on equity (ROE)

-85.9%

22.4%

-80.9%

-327.8%

-1198.6%

▼ 871 pts

Free cash flow margin

-441.7%

-260.0%

-1099.9%

-1955.6%

-927.6%

▲ >999 pts

Current ratio

4.52×

1.50×

2.99×

4.76×

3.09×

▼ 35%

Quick ratio

—

4.76×

3.08×

▼ 35%

Debt to equity

1.68×

0.68×

0.00×

4.46×

—

Interest coverage

—

-213.16×

-22504.83×

-28.58×

▲ 100%